308 results about "Subcutaneous injection" patented technology

The invention discloses a tree shrew depression model modeling method which comprises the following steps: (1) dissolving 20 mg of corticosterone in 10 microliters of DMSO (dimethylsulfoxide), and fixing the volume to 1 ml by normal saline; the method comprises the following steps: dissolving 100 mg of estradiol in 1 ml of DMSO (Dimethylsulfoxide) to prepare 100 mg / ml of estradiol stock solution; and (2) carrying out subcutaneous injection on the corticosterone solution prepared in the step (1) to tree shrews at 14: 00-16: 00 in the afternoon every day at the injection amount of 27 mu g / kg, diluting the estradiol stock solution prepared in the step (1) with normal saline after the corticosterone solution is injected for 1 hour, then carrying out subcutaneous injection on the tree shrews at the injection amount of 50-75 mu g / kg, and continuously injecting for 21 days to complete molding. According to the invention, a method of increasing the use dosage of corticosterone and simultaneously adding estradiol (estrogen with the highest in-vivo content and strongest activity) is adopted, so that the modeling time can be shortened. The corticosterone and the estradiol are combined for tree shrew depression modeling, so that the modeling time can be effectively shortened, and the optimal modeling effect is achieved by adopting a special estradiol dosage.

The present disclosure provides storage stable solid compositions including a biopharmaceutical agent and a polyacrylamide-based copolymer. The inventors have demonstrated that particular polyacrylamide-based copolymers can be used as stabilizing excipients in lyophilized formulations of biopharmaceutical agents. Also provided are methods of reconstituting and using the compositions, including methods of administering the reconstituted composition to a human subject in need thereof via injection, e.g., subcutaneous injection.

The present invention relates to a pharmaceutical composition comprising (a) a drug and (b) a human PH20 variant. The human PH20 variant included in the pharmaceutical composition according to the present invention comprises an alpha helix 8 sequence (S347-C381) selected from the wild-type human pH20 with the amino acid sequence SEQ ID NO:1 and an amino acid substitution at one or more positions of the connecting region (A333-R346) between alpha helix 7 and alpha helix 8, and is optionally cut at an amino acid located in the N-terminal or C-terminal region. In addition, the pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable additive, particularly a stabilizer. Due to the advantages of human PH20 variants, the pharmaceutical composition according to the present invention can show the maximum therapeutic effect of the drug used therewith.

An autonomous system and method thereof for mass individual treatment such as injection of livestock or wild animals from a herd or group for precise delivery of a technical treatment or substance to an animal by intramuscular (IM) injection, subcutaneous (SQ) injection, or any transdermal injection, spraying, pouring-on, tagging, cooling, pinning, gluing or saddling, is described. The system comprises an ecological and ergonomically-designed smart grooming passageway for a single animal to move into and be calm while safely and snugly embraced for injection, and then motivated to move forward, allowing the next animal to amble in, after injection. The system has an adjustable autonomous device carrying an injection assembly with a number of injectors for delivery of injectable substances, as well as pre-injection desensitization and disinfection, and comprising a temperature control means for maintaining optimal and constant temperature of injectable substances. A camera and sensor array send various data to a controller and processor to determine the optimal individualized treatment. The system then instructs the injection assembly to inject injectable substances into a predefined injection target triangle of the animal's triangular mass of muscle on the side of the neck or any other injection target, thus achieving the highest efficiency and least amount of damage and stress to the animal, without risk to humans.

The invention discloses an aprepitant nano suspension pharmaceutical composition and a preparation method thereof. The aprepitant nano suspension pharmaceutical composition comprises aprepitant, a space stabilizer, an electrostatic stabilizer and water, the steric stabilizer is selected from one or more of poloxamer F188, poloxamer F407 and polyvinylpyrrolidone K30, and the steric stabilizer is selected from one or more of poloxamer F188, poloxamer F407 and polyvinylpyrrolidone K30; the electrostatic stabilizer is lauryl sodium sulfate or PCM. By selecting a specific stabilizer and a preparation method, subcutaneous injection of aprepitant is realized, the stability of the medicine is remarkably improved, and the medicine loading capacity is increased. In addition, according to the method, the preparation process is simplified, the formula screening time is shortened, and therefore the overall preparation time is shortened.

The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.

The invention discloses a preparation method of a self-crosslinking hyaluronic acid microsphere without an exogenous crosslinking agent, which comprises the following steps: activating carboxyl on hyaluronic acid only by using an activator with good biocompatibility, carrying out esterification reaction on the activated carboxyl and hydroxyl on the hyaluronic acid, and curing and crosslinking water-in-oil emulsion at room temperature by continuously stirring to obtain the self-crosslinking hyaluronic acid microsphere without the exogenous crosslinking agent. The self-crosslinking hyaluronic acid microspheres are formed. As an exogenous cross-linking agent is not introduced, hyaluronic acid forms an ester bond through self-crosslinking after being activated instead of forming an amido bond with the exogenous cross-linking agent, and the formation of the ester bond can effectively improve the storage modulus of the hyaluronic acid microspheres. Compared with a commercially available sieved gel product, the self-crosslinked hyaluronic acid microsphere disclosed by the invention has the advantages that the crosslinking degree is higher, the immunogenicity risk of free HA is reduced, the self-crosslinked hyaluronic acid microsphere is suitable for deep or subcutaneous injection of dermis, and a more uniform three-dimensional support is provided.

The inventors provide strong evidence that FGFR3 gain of function mutation expressed in the brain induces cognitive and behavior deficit. To provide evidence that the constitutive activation of FGFR3 and its downstream signalling pathways are responsible for these behavioral impairments, the inventors treated the Fgfr3A385E / + mice using subcutaneous injection of catechin isomers for at least seven days. In addition the inventors treated the Fgfr3N534K / + mice with bottle treatments. The treatment rescues the anomalies in short-term learning and in coping strategy. The present invention thus relates to a method of treating a FGFR3-related cognitive deficit in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one catechin.

The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.

To provide a highly concentrated liquid antibody formulation that is storage stable and suitable for subcutaneous administration.SOLUTION: The present disclosure inter alia provides a liquid pharmaceutical formulation comprising a) 150 mg / ml of an anti-IL-23p19 antibody, the antibody comprising a specific light chain amino acid sequence and a specific heavy chain amino acid sequence; b) a polyol; and c) a surfactant.SELECTED DRAWING: None

The invention discloses a method for establishing a cat osteoarthritis pain model, which comprises the following steps of: performing experimental research on immunogen, drug concentration, immunization frequency, administration route, injection dosage and the like, and adopting collagen immunogen and 1% carrageenan immunogen as mixed immunogen; a cat is immunized by adopting a two-point injection mode of subcutaneous injection near a shoulder blade and plantar subcutaneous injection, the immunization procedure adopts twice immunization of 0 day and 7 days, a simple and efficient cat osteoarthritis pain model is successfully constructed, the model has obvious joint and claw swelling, a cat claw retraction threshold value is reduced, a TNF-a factor is obviously increased, and the model can be used for researching the pain of the cat osteoarthritis, the pain of the cat osteoarthritis and the pain of the cat osteoarthritis. The method can be used for researching the pathogenesis, pathological change, pain mechanism and OA treatment method of the cat osteoarthritis, and can also be used for evaluating the clinical effect of a novel analgesic drug for the cat osteoarthritis.

Disclosed herein are liquid formulations comprising high concentrations humanized antibodies for treating an IL-6-related disease. The antibody formulation provides good antibody stability, acceptable viscosity and osmolarity for subcutaneous injection, and prevents aggregation, degradation of the monoclonal antibody, and acidic isomer increase. The formulation is applicable in stabilizing the structure and function of the humanized antibody.

The invention relates to the technical field related to biological medicine, and particularly provides an anti-bovine rotavirus recombinant protein vaccine composition and application thereof. The recombinant protein vaccine composition for resisting bovine rotavirus comprises a first recombinant protein vaccine which is administrated through nasal drop and a second recombinant protein vaccine which is administrated through subcutaneous injection, the first recombinant protein vaccine comprises VP6 recombinant protein and LTB recombinant protein; the second recombinant protein vaccine comprises VP7 recombinant protein. According to the recombinant protein vaccine disclosed by the invention, the combination of the first recombinant protein vaccine which is administrated through nasal dripping and the second recombinant protein vaccine which is administrated through subcutaneous injection is used, so that the comprehensiveness of preventing the bovine rotavirus is improved.

Most therapeutic treatments require dose adjustment after initial administration. Dosage adjustment is crucial to ensuring optimal safety and efficacy characteristics of the treatment. Gene therapy is inherently limited by the inability to adjust the dose after initial administration. This invention describes a genetic element capable of dose adjustment after the initial administration of gene therapy. The realization of dose adjustment allows for the replacement of multiple subcutaneous protein injection regimens with single-injection gene therapy, thereby improving pharmacokinetics, safety / efficacy characteristics, medication adherence, and reducing healthcare costs.

The present invention relates to a pharmaceutical composition comprising (a) a drug and (b) a human PH20 variant. The human PH20 variant comprised in the pharmaceutical composition according to the present invention comprises amino acid substitutions at one or more positions selected from the alpha helix 8 sequence (S347-C381) and a linking region (A333-R346) between alpha helix 7 and alpha helix 8 on wild-type human pH20 having the amino acid sequence SEQ ID NO: 1, and optionally cleaved at the amino acid located at the N-terminal or C-terminal region. In addition, the pharmaceutical composition according to the present invention may further comprise a pharmaceutically acceptable additive, in particular a stabilizer. Due to the advantages of the human PH20 variant, the pharmaceutical composition according to the present invention can exhibit a maximum therapeutic effect of a drug used therewith.

The present invention relates to aqueous compositions comprising dantrolene and optionally also at least one additional active principle, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic / cosmetic purposes. The compositions can be administered in any suitable way but are advantageous in that they are particularly well adapted to intramuscular injection, subcutaneous injection and / or intradermal injection.

The utility model discloses a chuck type subcutaneous injection alternate positioning disc which comprises a base, a connecting rod is fixedly installed on the outer surface of the upper end of the base, an automatic positioning rotary injection fixing device used for improving positioning convenience is arranged on the outer ring of the connecting rod, and the automatic positioning rotary injection fixing device comprises a damping rotating shaft. According to the chuck type hypodermic injection alternate positioning disc, the automatic positioning rotary injection fixing device is arranged, the structure is simple, operation is convenient and fast, injection parts can be rapidly adjusted, the injection positions can be rapidly positioned and recorded, the injection parts cannot be concentrated in a short time, and the working efficiency is improved. Stable and reliable support can be provided for normative, accurate and ordered injection work of medical staff, and the situation that adverse reactions occur to a patient due to the fact that injection parts are too concentrated within a short time can be avoided.

A pharmaceutical combination for subcutaneous administration and use thereof are provided. The pharmaceutical combination as described herein for subcutaneous administration includes a hyaluronidase and an antibody-drug conjugate. The antibody-drug conjugate includes a fragment of a bioactive molecule, and the bioactive molecule has moderate toxicity. The pharmaceutical combination can achieve a larger volume and a larger dose of administration, and the side reaction is not enhanced.

The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 600 mg to about 1000 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

The present invention discloses a preparation method of injectable sodium hyaluronate-coated polylactic acid microspheres. The sodium hyaluronate-coated polylactic acid microspheres are prepared by the emulsion method. On the one hand, by utilizing the good hydrophilic property of hyaluronic acid itself, the freeze-dried sodium hyaluronate-coated polylactic acid microspheres can be well redissolved in injection water, greatly reducing problems such as long redissolution time and uneven particle dispersion. On the other hand, after the sodium hyaluronate-coated polylactic acid microspheres are subcutaneously injected, the first thing they contact is sodium hyaluronate with better biocompatibility, avoiding the more irritating inflammatory phenomenon caused by direct contact with the polylactic acid microspheres. As the sodium hyaluronate on the outer layer of the microspheres is enzymatically degraded, the inner layer of polylactic acid microspheres will be exposed, further playing a role in stimulating the body's own collagen production. In addition, the preparation method of the present invention has simple technological steps and is suitable for large-scale preparation for industrial applications.

The present inventors provide strong evidence that FGFR3 gain-of-function mutations expressed in the brain induce cognitive and behavioral disorders. To provide evidence that the constitutive activation of FGFR3 and its downstream signaling pathways are responsible for these behavioral disorders, the present inventors used subcutaneous injections of catechin isomers for at least 7 days to investigate the effects of FGFR3 on cognitive and behavioral disorders. A385E / + Furthermore, the present inventors treated mice with Fgfr3 N534K / + Mice are treated with bottle treatment. Treatment restores abnormalities in short-term learning and coping strategies.Therefore, the present invention relates to a method for treating FGFR3-related cognitive impairment in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one catechin.

The utility model discloses an alternate positioning card for continuous hypodermic injection of an anticoagulant in the abdomen, which comprises a positioning disc, the positioning disc is composed of a rotating wheel card and seven injection areas arranged on the rotating wheel card at equal intervals in a surrounding manner, the seven injection areas respectively correspond to seven days in a week in sequence, and corresponding week marks are arranged on the injection areas. Positioning scales are arranged on the edges of the seven injection areas; each injection area is divided into a first injection area and a second injection area through a spacing bar, and the first injection area and the second injection area correspond to a single circle and a double circle respectively; according to the utility model, the injection areas corresponding to seven days in a week are respectively arranged, so that a patient can successively inject at a specified date according to the seven areas, and the problem of repeated injection at one position is avoided; by arranging the first injection area and the second injection area corresponding to single and double weeks, a patient can distribute two areas, one area performs single-week injection, and the other area performs double-week injection, so that injection confusion is avoided.

The present disclosure provides methods for treating thyroid eye disease, comprising subcutaneously administering a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment to a patient in need of treatment. Also provided herein are pharmacologically active agents, compositions, methods, and / or administration schedules for the treatment of thyroid eye disease.

This invention belongs to the field of vertebrate technology, specifically relating to a method for constructing a complex inflammatory animal model in middle-aged and elderly individuals and its related applications. The method includes: selecting adult animals for adaptive feeding, daily subcutaneous injection of D-galactose to establish a susceptibility to aging and oxidative stress, and administering sodium dextran sulfate (DSS) solution within a specific time window to induce intestinal inflammation, forming a complex inflammatory state through gut-hepatic axis interactions. The constructed animal model simultaneously exhibits intestinal inflammatory damage, abnormal hepatic oxidative stress, and aging-related characteristics, realistically simulating the pathological process of gut-hepatic axis dysfunction in middle-aged and elderly individuals. This model is suitable for screening and evaluating drugs, medical nutrition products, and functional foods that improve gut-hepatic axis dysfunction, providing a reliable technical platform for research on related disease mechanisms and the development of interventional substances.

The present invention relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition comprising the same for subcutaneous administration, and a method for preparing the same. In the case of using the preparation method of the present invention, nanoparticles comprising sirolimus and albumin having excellent stability of particle size distribution can be prepared, the prepared nanoparticles can be prepared as a pharmaceutical composition suitable for subcutaneous injection, and the increase in administration dose and the convenience of administration can be improved.

The invention relates to a device (100), particularly a cosmetic one, for the subcutaneous injection of gas, in particular carbon dioxide (CO2), comprising a gas reservoir (10) in fluidic communication with a hollow microneedle (4) having an internal channel of mean internal transverse dimension (IDmoy), the hollow injection microneedle (4) having a length (L) less than or equal to 250 mm and greater than or equal to 70 mm. [Fig. 1]

The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg / mL or more suspended in a non-aqueous suspension vehicle where the viscocity of the suspension vehicle is less than about 20 centipoise. Also disclosed are: a subcutaneous administration device with the formulation therein, a method of making the formulation, a method of making an article of manufacture comprising the suspension formulation, use of the formulation in the preparation of a medicament, and a method of treating a patient with the formulation.

A polyethylene glycol modified kinine or its derivative and its use in drugs. The present invention uses PEG modification technology to significantly extend the half-life of kinine and simultaneously exert its biological activity, solving the problem of lack of druggability due to a short half-life. PEG modifiers include, but are not limited to, SPA, SCM, and SS modifiers. They may be linear or branched PEG modifiers. The modified kinine mutant of the present invention has an extended half-life while retaining its affinity to the receptor, and further has a better efficacy after PEG modification than wild-type kinine, further improving the druggability of kinine. The PEG modified kinine of the present invention exhibits remarkable drug efficacy even when administered by various routes. In particular, subcutaneous injection and oral administration are convenient for clinical use, effectively improve patient compliance, and are suitable for long-term treatment administration such as the recovery treatment of stroke patients.

The present invention provides an injectable depot composition comprising enavogliflozin and a low-dose liraglutide. A combination regimen of enavogliflozin and a low-dose liraglutide provides a synergistic effect in the treatment of obesity compared to the sole administration of either of the drugs. In addition, compared to the sole administration of liraglutide, the administered dose of liraglutide can be reduced, and thus direct causes of gastrointestinal and cardiovascular side effects of liraglutide can be mitigated. In addition, the present invention has the advantage of additionally providing the effect of alleviating metabolic diseases and cardiovascular diseases related to blood glucose, blood lipids, blood pressure, fatty liver, and the like through combined administration with enavogliflozin. Furthermore, the depot composition of enavogliflozin and liraglutide according to the present invention can significantly improve medication convenience and medication adherence for a patient compared to existing liraglutide formulations, which are subcutaneously injected once a day, by unifying the route of administration and improving the administration cycle.